Siegall Clay B's Form 4 filing
Immunome Inc. (IMNM) · filed Nov 25, 2024
- Accession no.
- 0001415889-24-027601
- Filed
- Nov 25, 2024
- Trade date
- Nov 21-22, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $962.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Siegall Clay BCIK 0001167496 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2024 | Common Stock | PPurchaseAcquired | +66,057 | $9.54 | +$630,183.78 | 485,693 | Direct | |
| Nov 22, 2024 | Common Stock | PPurchaseAcquired | +33,943 | $9.78 | +$331,962.54 | 519,636 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.